Sodium-glucose cotransporter 2 (SGLT2) inhibitors have introduced a fundamental change in how we treat chronic kidney disease (CKD) and heart failure. Initially developed to reduce blood sugar, the...
No takes yet. Share an insight, caveat, or question.
Delrue et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: